Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Dunmore

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Proceedings of the American Thoracic Society|October 30, 2010
Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertensionWei Li, Benjamin J Dunmore, Nicholas W Morrell
Biochemical and Biophysical Research Communications|June 8, 2006
Mutant Tie2 causing venous malformation signals through ShcPaul N Morris, Benjamin J Dunmore, Nicholas P J Brindle
Developmental Dynamics : an Official Publication of the American Association of Anatomists|April 18, 2022
An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertensionPaul D Upton, Benjamin J Dunmore, Wei Li, et al.
Blood|August 23, 2003
ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1Amir Tadros, David P Hughes, Benjamin J Dunmore, et al.
Journal of Vascular Surgery|January 11, 2007
Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaquesBenjamin J Dunmore, Mark J McCarthy, A Ross Naylor, et al.
Pulmonary Circulation|May 7, 2025
Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor ExpressionBenjamin J Dunmore, Nobuhiro Kikuchi, Wei Li, et al.
Cardiovascular Research|January 5, 2021
Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleusBenjamin J Dunmore, Rowena J Jones, Mark R Toshner, et al.
American Journal of Respiratory Cell and Molecular Biology|April 18, 2013
Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertensionKylie M Drake, Benjamin J Dunmore, Lauren N McNelly, et al.
Vascular Pharmacology|May 25, 2024
SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cellsSarah L Mirza, Paul D Upton, Joshua Hodgson, et al.
Circulation Research|March 1, 2013
Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradationLu Long, Xudong Yang, Mark Southwood, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Proceedings of the American Thoracic Society|October 30, 2010
Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertensionWei Li, Benjamin J Dunmore, Nicholas W Morrell
Biochemical and Biophysical Research Communications|June 8, 2006
Mutant Tie2 causing venous malformation signals through ShcPaul N Morris, Benjamin J Dunmore, Nicholas P J Brindle
Developmental Dynamics : an Official Publication of the American Association of Anatomists|April 18, 2022
An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertensionPaul D Upton, Benjamin J Dunmore, Wei Li, et al.
Blood|August 23, 2003
ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1Amir Tadros, David P Hughes, Benjamin J Dunmore, et al.
Journal of Vascular Surgery|January 11, 2007
Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaquesBenjamin J Dunmore, Mark J McCarthy, A Ross Naylor, et al.
Pulmonary Circulation|May 7, 2025
Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor ExpressionBenjamin J Dunmore, Nobuhiro Kikuchi, Wei Li, et al.
Cardiovascular Research|January 5, 2021
Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleusBenjamin J Dunmore, Rowena J Jones, Mark R Toshner, et al.
American Journal of Respiratory Cell and Molecular Biology|April 18, 2013
Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertensionKylie M Drake, Benjamin J Dunmore, Lauren N McNelly, et al.
Vascular Pharmacology|May 25, 2024
SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cellsSarah L Mirza, Paul D Upton, Joshua Hodgson, et al.
Circulation Research|March 1, 2013
Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradationLu Long, Xudong Yang, Mark Southwood, et al.
Pageof 4